Orion Oyj (ORINY)

Market Cap	13.05B +18.0%
Revenue (ttm)	2.35B +22.7%
Net Income	670.74M +55.3%
EPS	4.77 +55.1%
Shares Out	n/a
PE Ratio	19.46
Forward PE	18.21
Dividend	0.51 (1.10%)
Ex-Dividend Date	Mar 26, 2026

Volume	4
Open	47.16
Previous Close	45.77
Day's Range	45.77 - 47.19
52-Week Range	30.89 - 47.19
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 4,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORINY

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error